Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule Summary
Background: Real-world data describing the impact of incident bullous pemphigoid (BP) on patients and health care resource utilization (HCRU) are limited. Objective: To examine characteristics, treatment patterns, HCRU, and costs for incident BP. Methods: Retrospective analysis of 2015 to 2019 US he...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | JAAD International |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666328723000871 |
| _version_ | 1797671431876640768 |
|---|---|
| author | Heide A. Stirnadel-Farrant, PhD Xiao Xu, PhD Justin Kwiatek, PharmD Priya Jain, MBBS, MBA Juliana Meyers, MA Sean Candrilli, PhD Daniel Mines, MD, MSCE Catherine J. Datto, MD, MS |
| author_facet | Heide A. Stirnadel-Farrant, PhD Xiao Xu, PhD Justin Kwiatek, PharmD Priya Jain, MBBS, MBA Juliana Meyers, MA Sean Candrilli, PhD Daniel Mines, MD, MSCE Catherine J. Datto, MD, MS |
| author_sort | Heide A. Stirnadel-Farrant, PhD |
| collection | DOAJ |
| description | Background: Real-world data describing the impact of incident bullous pemphigoid (BP) on patients and health care resource utilization (HCRU) are limited. Objective: To examine characteristics, treatment patterns, HCRU, and costs for incident BP. Methods: Retrospective analysis of 2015 to 2019 US health insurance claims for patients ≥18 years with an incident BP diagnosis. Patients with BP were matched to those without on demographic and clinical characteristics. Statistics were descriptive. Results: The mean Charlson Comorbidity Index score was higher for patients with BP (n = 1108) than without (n = 4621) at baseline (mean [SD]: 3.3 [2.7] vs 2.8 [2.4]) and during follow-up (5.0 [4.9] vs 3.7 [3.0]). Hypertension, diabetes, skin ulcers, chronic pulmonary disease, dyslipidemia, sleep disorders, and congestive heart failure were higher with BP. Most patients with BP received antibiotics (>80%) and/or corticosteroids (>90%). Hospitalizations were more common (44.0% vs 17.1%) and monthly all-cause health care costs more than double ($3214 vs $1353) in patients with BP than without. Limitations: Diagnoses were based on billing codes. HCRU claims data may not reflect the true number of encounters. Conclusion: Incident BP is associated with considerable morbidity, HCRU, and costs. More effective, targeted treatments are needed to improve quality of life, while minimizing exposure to systemic corticosteroids. |
| first_indexed | 2024-03-11T21:15:27Z |
| format | Article |
| id | doaj.art-e820ee217aef49159733ed8eb45a8acb |
| institution | Directory Open Access Journal |
| issn | 2666-3287 |
| language | English |
| last_indexed | 2024-03-11T21:15:27Z |
| publishDate | 2023-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JAAD International |
| spelling | doaj.art-e820ee217aef49159733ed8eb45a8acb2023-09-29T04:45:11ZengElsevierJAAD International2666-32872023-12-0113117125Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule SummaryHeide A. Stirnadel-Farrant, PhD0Xiao Xu, PhD1Justin Kwiatek, PharmD2Priya Jain, MBBS, MBA3Juliana Meyers, MA4Sean Candrilli, PhD5Daniel Mines, MD, MSCE6Catherine J. Datto, MD, MS7BioPharmaceuticals Medical, AstraZeneca, Cambridge, UKBioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MarylandBioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MarylandBioPharmaceuticals Medical, AstraZeneca, Cambridge, UKRTI Health Solutions, Research Triangle Park, North CarolinaRTI Health Solutions, Research Triangle Park, North CarolinaRTI Health Solutions, Research Triangle Park, North CarolinaLate-Stage Development, Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland; Correspondence to: Catherine J. Datto, MD, MS, AstraZeneca, 1 MedImmune Way, Gaithersburg, MD 20878.Background: Real-world data describing the impact of incident bullous pemphigoid (BP) on patients and health care resource utilization (HCRU) are limited. Objective: To examine characteristics, treatment patterns, HCRU, and costs for incident BP. Methods: Retrospective analysis of 2015 to 2019 US health insurance claims for patients ≥18 years with an incident BP diagnosis. Patients with BP were matched to those without on demographic and clinical characteristics. Statistics were descriptive. Results: The mean Charlson Comorbidity Index score was higher for patients with BP (n = 1108) than without (n = 4621) at baseline (mean [SD]: 3.3 [2.7] vs 2.8 [2.4]) and during follow-up (5.0 [4.9] vs 3.7 [3.0]). Hypertension, diabetes, skin ulcers, chronic pulmonary disease, dyslipidemia, sleep disorders, and congestive heart failure were higher with BP. Most patients with BP received antibiotics (>80%) and/or corticosteroids (>90%). Hospitalizations were more common (44.0% vs 17.1%) and monthly all-cause health care costs more than double ($3214 vs $1353) in patients with BP than without. Limitations: Diagnoses were based on billing codes. HCRU claims data may not reflect the true number of encounters. Conclusion: Incident BP is associated with considerable morbidity, HCRU, and costs. More effective, targeted treatments are needed to improve quality of life, while minimizing exposure to systemic corticosteroids.http://www.sciencedirect.com/science/article/pii/S2666328723000871antibioticsautoimmune diseaseblistering skin diseasebullous pemphigoidburden of diseaseclinical characteristics |
| spellingShingle | Heide A. Stirnadel-Farrant, PhD Xiao Xu, PhD Justin Kwiatek, PharmD Priya Jain, MBBS, MBA Juliana Meyers, MA Sean Candrilli, PhD Daniel Mines, MD, MSCE Catherine J. Datto, MD, MS Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule Summary JAAD International antibiotics autoimmune disease blistering skin disease bullous pemphigoid burden of disease clinical characteristics |
| title | Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule Summary |
| title_full | Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule Summary |
| title_fullStr | Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule Summary |
| title_full_unstemmed | Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule Summary |
| title_short | Characteristics, treatment patterns, health care resource utilization and costs in patients with bullous pemphigoid: A retrospective analysis of US health insurance claims dataCapsule Summary |
| title_sort | characteristics treatment patterns health care resource utilization and costs in patients with bullous pemphigoid a retrospective analysis of us health insurance claims datacapsule summary |
| topic | antibiotics autoimmune disease blistering skin disease bullous pemphigoid burden of disease clinical characteristics |
| url | http://www.sciencedirect.com/science/article/pii/S2666328723000871 |
| work_keys_str_mv | AT heideastirnadelfarrantphd characteristicstreatmentpatternshealthcareresourceutilizationandcostsinpatientswithbullouspemphigoidaretrospectiveanalysisofushealthinsuranceclaimsdatacapsulesummary AT xiaoxuphd characteristicstreatmentpatternshealthcareresourceutilizationandcostsinpatientswithbullouspemphigoidaretrospectiveanalysisofushealthinsuranceclaimsdatacapsulesummary AT justinkwiatekpharmd characteristicstreatmentpatternshealthcareresourceutilizationandcostsinpatientswithbullouspemphigoidaretrospectiveanalysisofushealthinsuranceclaimsdatacapsulesummary AT priyajainmbbsmba characteristicstreatmentpatternshealthcareresourceutilizationandcostsinpatientswithbullouspemphigoidaretrospectiveanalysisofushealthinsuranceclaimsdatacapsulesummary AT julianameyersma characteristicstreatmentpatternshealthcareresourceutilizationandcostsinpatientswithbullouspemphigoidaretrospectiveanalysisofushealthinsuranceclaimsdatacapsulesummary AT seancandrilliphd characteristicstreatmentpatternshealthcareresourceutilizationandcostsinpatientswithbullouspemphigoidaretrospectiveanalysisofushealthinsuranceclaimsdatacapsulesummary AT danielminesmdmsce characteristicstreatmentpatternshealthcareresourceutilizationandcostsinpatientswithbullouspemphigoidaretrospectiveanalysisofushealthinsuranceclaimsdatacapsulesummary AT catherinejdattomdms characteristicstreatmentpatternshealthcareresourceutilizationandcostsinpatientswithbullouspemphigoidaretrospectiveanalysisofushealthinsuranceclaimsdatacapsulesummary |